Radiology Personnel

Joseph Rajendran, M.D.



Dr. Rajendran is a nuclear medicine physician and a professor of radiology. He specializes in various therapies using radiopharmaceuticals including radioimmunotherapy and radiation treatment planning using molecular imaging.

He completed his medical degree at Madurai Medical College and his residency at UW. He is board certified in nuclear medicine and nuclear cardiology.

He is a fellow of the American College of Nuclear Medicine and American Society of Nuclear Cardiology. He is an adjunct professor with the Department of Radiation Oncology.

Recent Publications

See all publications on Scopus

Volume dependence in hypoxia-targeted dose escalation
Chvetsov A., Zeng J., Rajendran J.
Medical Physics. 2018 Jan

Theoretical effectiveness of cell survival in fractionated radiotherapy with hypoxia-targeted dose escalation
Chvetsov A., Rajendran J., Zeng J., Patel S., Bowen S., Kim E.
Medical Physics. 2017 Jan:1-8

High-dose CD20-targeted radioimmunotherapy-based autologous transplantation improves outcomes for persistent mantle cell lymphoma
Cassaday R., Stevenson P., Gooley T., Chauncey T., Pagel J., Rajendran J., Till B., Philip M., Orozco J., Bensinger W., Holmberg L., Shustov A., Green D., Smith S., Libby E., Maloney D., Press O., Gopal A.
British Journal of Haematology. 2015 Dec:788-797

<sup>18</sup>F-fluoromisonidazole quantification of hypoxia in human cancer patients using image-derived blood surrogate tissue reference regions
Muzi M., Peterson L., O'Sullivan J., Fink J., Rajendran J., McLaughlin L., Muzi J., Mankoff D., Krohn K.
Journal of Nuclear Medicine. 2015 Jan:1223-1228

F-18 fluoromisonidazole for imaging tumor hypoxia: Imaging the microenvironment for personalized cancer therapy
Rajendran J., Krohn K.
Seminars in Nuclear Medicine. 2015 Jan:151-162

Long-Term Outcomes of Patients with Persistent Indolent BCell Malignancies Undergoing Nonmyeloablative Allogeneic Transplantation
Cassaday R., Storer B., Sorror M., Sandmaier B., Guthrie K., Maloney D., Rajendran J., Pagel J., Flowers M., Green D., Rezvani A., Storb R., Press O., Gopal A.
Biology of Blood and Marrow Transplantation. 2015 Jan:281-287

Myeloablative I-131-tositumomab with escalating doses of fludarabine and autologous hematopoietic transplantation for adults age ≥ 60 years with B cell lymphoma
Gopal A., Gooley T., Rajendran J., Pagel J., Fisher D., Maloney D., Appelbaum F., Cassaday R., Shields A., Press O.
Biology of Blood and Marrow Transplantation. 2014 Jan:770-775

90Y-ibritumomab tiuxetan therapy in allogeneic transplantation in B-cell lymphoma with extensive marrow involvement and chronic lymphocytic leukemia: Utility of pretransplantation biodistribution
Matesan M., Rajendran J., Press O., Maloney D., Storb R., Cassaday R., Pagel J., Oliveira G., Gopal A.
Nuclear Medicine Communications. 2014 Jan:1132-1142

Radiolabeled anti-CD45 antibody with reduced-intensity conditioning and allogeneic transplantation for younger patients with advanced acute myeloid leukemia or myelodysplastic syndrome
Mawad R., Gooley T., Rajendran J., Fisher D., Gopal A., Shields A., Sandmaier B., Sorror M., Deeg H., Storb R., Green D., Maloney D., Appelbaum F., Press O., Pagel J.
Biology of Blood and Marrow Transplantation. 2014 Jan:1363-1368

131I-tositumomab myeloablative radioimmunotherapy for non-Hodgkin’s lymphoma: Radiation dose to the testes
Hattori N., Gopal A., Shields A., Fisher D., Gooley T., Pagel J., Press O., Rajendran J.
Nuclear Medicine Communications. 2012 Dec:1225-1231